These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29264970)

  • 21. Vaccines for sexually transmitted infections.
    Rupp RE; Stanberry LR; Rosenthal SL
    Pediatr Ann; 2005 Oct; 34(10):818-20, 822-4. PubMed ID: 16285635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute pelvic inflammatory disease.
    Eschenbach DA
    Urol Clin North Am; 1984 Feb; 11(1):65-81. PubMed ID: 6369707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary approaches to designing and evaluating vaccines against Chlamydia.
    Igietseme JU; Eko FO; Black CM
    Expert Rev Vaccines; 2003 Feb; 2(1):129-46. PubMed ID: 12901604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chlamydia trachomatis infection control programs: lessons learned and implications for vaccine development.
    Chavez JM; Vicetti Miguel RD; Cherpes TL
    Infect Dis Obstet Gynecol; 2011; 2011():754060. PubMed ID: 22144851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection.
    Jiang P; Du W; Xiong Y; Lv Y; Feng J; Zhu S; Xue X; Chen S; Zhang L
    Oncotarget; 2015 Dec; 6(41):43281-92. PubMed ID: 26657117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chlamydia vaccines: strategies and status.
    Igietseme JU; Black CM; Caldwell HD
    BioDrugs; 2002; 16(1):19-35. PubMed ID: 11908999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.
    Vasilevsky S; Greub G; Nardelli-Haefliger D; Baud D
    Clin Microbiol Rev; 2014 Apr; 27(2):346-70. PubMed ID: 24696438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of a multi-epitope protein vaccine against herpes simplex virus, human papillomavirus and Chlamydia trachomatis as the main causes of sexually transmitted diseases.
    Dorosti H; Eskandari S; Zarei M; Nezafat N; Ghasemi Y
    Infect Genet Evol; 2021 Dec; 96():105136. PubMed ID: 34775078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chlamydia trachomatis: a frequently overlooked public health menace.
    Katz AR
    Hawaii Med J; 1989 May; 48(5):156, 159-60. PubMed ID: 2753693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delivery of Chlamydia vaccines.
    Igietseme J; Eko F; He Q; Bandea C; Lubitz W; Garcia-Sastre A; Black C
    Expert Opin Drug Deliv; 2005 May; 2(3):549-62. PubMed ID: 16296774
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    de la Maza LM; Darville TL; Pal S
    Expert Rev Vaccines; 2021 Apr; 20(4):421-435. PubMed ID: 33682583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct.
    Rey-Ladino J; Koochesfahani KM; Zaharik ML; Shen C; Brunham RC
    Infect Immun; 2005 Mar; 73(3):1568-77. PubMed ID: 15731055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the number of genital chlamydial infections in the United States.
    Judson FN
    J Reprod Med; 1985 Mar; 30(3 Suppl):269-72. PubMed ID: 4020783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chlamydia trachomatis infection of the male genital tract: an update.
    Mackern-Oberti JP; Motrich RD; Breser ML; Sánchez LR; Cuffini C; Rivero VE
    J Reprod Immunol; 2013 Nov; 100(1):37-53. PubMed ID: 23870458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The incidence of urogenital Chlamydia trachomatis infections among patients in Kumasi, Ghana.
    Drescher C; Elkins TE; Adkeo O; Akins-Bekoe P; Agbemadzo T; Foster RL; Martey JO
    Int J Gynaecol Obstet; 1988 Dec; 27(3):381-3. PubMed ID: 2904902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles.
    Sahu R; Verma R; Dixit S; Igietseme JU; Black CM; Duncan S; Singh SR; Dennis VA
    Expert Rev Vaccines; 2018 Mar; 17(3):217-227. PubMed ID: 29382248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genital Chlamydia trachomatis: an update.
    Malhotra M; Sood S; Mukherjee A; Muralidhar S; Bala M
    Indian J Med Res; 2013 Sep; 138(3):303-16. PubMed ID: 24135174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Female genital Chlamydia trachomatis infection: where are we heading?
    Mylonas I
    Arch Gynecol Obstet; 2012 May; 285(5):1271-85. PubMed ID: 22350326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model.
    Andrew DW; Hafner LM; Beagley KW; Timms P
    J Reprod Immunol; 2011 Sep; 91(1-2):9-16. PubMed ID: 21856018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response Profile.
    Picard MD; Bodmer JL; Gierahn TM; Lee A; Price J; Cohane K; Clemens V; DeVault VL; Gurok G; Kohberger R; Higgins DE; Siber GR; Flechtner JB; Geisler WM
    Clin Vaccine Immunol; 2015 Nov; 22(11):1206-18. PubMed ID: 26446421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.